AMG 706
information and resources from the National Cancer Institute
AMG 706
An orally bioavailable multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.
|
|
|
|
news articles
UPDATE 1-Reuters Summit-Amgen confident of 4 drug approvals Nov 8, 2005
Reuters The four products are panitumumab, an antibody being studied as a treatment for colon cancer, osteoporosis treatment denosumab, AMG 706, a cancer drug designed ...
Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased ... Oct 19, 2005
PharmaLive.com (press release), AMG 706: Amgen expects final data to be available in the first half of 2006 from its Phase 2 study of AMG 706 in patients with gastrointestinal stromal tumors ...
|
|
